Healthcare's most expensive failures often occur at the same seam: where a strategy that appeared sound in the boardroom meets the clinical, regulatory, financial, and operational reality in which it must work. Every technology cycle exposes that gap, and today AI is its most consequential expression. The investments are substantial, the effects reach across the enterprise, and few leaders have worked in all the environments where those decisions take effect.

Scott Schell has. He has built clinical, cancer, and population-health programs inside major health systems; led a national care-management business through acquisition and a molecular-diagnostics company through recapitalization and turnaround; advised pharma and medtech companies on bringing products through trials and regulation; and turned emerging technology into operating models that survive contact with clinical, operational, and financial reality. That work spans the bench, the bedside, the boardroom, and the payer, regulatory, and capital structures that shape healthcare.

He works across healthcare's clinical, scientific, commercial, and technical boundaries to test consequential strategies against the realities that determine whether they will scale, and to align the people, decisions, and operating models needed to build what works, redirect what does not, and act before failure becomes expensive.